EA200701541A1 - Применение оксикодона для лечения висцеральной боли - Google Patents

Применение оксикодона для лечения висцеральной боли

Info

Publication number
EA200701541A1
EA200701541A1 EA200701541A EA200701541A EA200701541A1 EA 200701541 A1 EA200701541 A1 EA 200701541A1 EA 200701541 A EA200701541 A EA 200701541A EA 200701541 A EA200701541 A EA 200701541A EA 200701541 A1 EA200701541 A1 EA 200701541A1
Authority
EA
Eurasian Patent Office
Prior art keywords
visceral pain
oxycodon
treatment
application
prescribing
Prior art date
Application number
EA200701541A
Other languages
English (en)
Other versions
EA013544B1 (ru
Inventor
Асбьёрн Мор Древес
Ларс Аренд Нильсен
Original Assignee
Еуро-Селтик С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200701541(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Еуро-Селтик С.А. filed Critical Еуро-Селтик С.А.
Publication of EA200701541A1 publication Critical patent/EA200701541A1/ru
Publication of EA013544B1 publication Critical patent/EA013544B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

Эффективно лечить умеренную и тяжелую висцеральную боль можно путем назначения анальгетиков, включая опиоид оксикодон или же его соли с приемлемыми фармацевтическими свойствами. Висцеральную боль и особенно острую висцеральную боль можно эффективно лечить, назначая оксикодон в дозировках более низких по сравнению с соответствующими дозировками других опиоидов, таких как морфин.
EA200701541A 2005-01-18 2006-01-17 Применение оксикодона для лечения висцеральной боли EA013544B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (2)

Publication Number Publication Date
EA200701541A1 true EA200701541A1 (ru) 2008-02-28
EA013544B1 EA013544B1 (ru) 2010-06-30

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701541A EA013544B1 (ru) 2005-01-18 2006-01-17 Применение оксикодона для лечения висцеральной боли

Country Status (32)

Country Link
US (2) US20080200493A1 (ru)
EP (1) EP1838318B1 (ru)
JP (1) JP5049139B2 (ru)
KR (10) KR20200128451A (ru)
CN (1) CN101106996B (ru)
AP (1) AP2249A (ru)
AR (1) AR052880A1 (ru)
AT (2) ATE446092T1 (ru)
AU (1) AU2006207498B2 (ru)
BR (1) BRPI0606247A2 (ru)
CA (1) CA2595043C (ru)
CY (1) CY1109660T1 (ru)
DE (2) DE602006009899D1 (ru)
DK (2) DK1838318T3 (ru)
EA (1) EA013544B1 (ru)
ES (1) ES2333901T3 (ru)
HK (1) HK1107933A1 (ru)
HR (1) HRP20090679T1 (ru)
IL (1) IL184530A (ru)
ME (1) ME01066B (ru)
MX (1) MX2007007207A (ru)
MY (1) MY144471A (ru)
NO (1) NO338968B1 (ru)
NZ (1) NZ555852A (ru)
PL (1) PL1838318T3 (ru)
PT (1) PT1838318E (ru)
RS (1) RS51069B (ru)
SI (1) SI1838318T1 (ru)
TW (1) TWI432196B (ru)
UA (1) UA85471C2 (ru)
WO (1) WO2006077212A1 (ru)
ZA (1) ZA200705231B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
BRPI0907135B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
DK2710039T3 (en) 2011-05-20 2019-04-01 Alderbio Holdings Llc ANTI-CGRP COMPOSITIONS AND APPLICATION THEREOF
SG194973A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
NZ332039A (en) * 1996-03-25 2000-06-23 Lilly Co Eli Method for treating pain using olanzapine and NSAIDs
UA81224C2 (ru) * 2001-05-02 2007-12-25 Euro Celtic S A Дозированная форма оксикодона и ее применение
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
CY1109660T1 (el) 2014-08-13
BRPI0606247A2 (pt) 2009-06-09
JP5049139B2 (ja) 2012-10-17
KR20120089710A (ko) 2012-08-13
DK1838318T3 (da) 2010-01-04
JP2008526927A (ja) 2008-07-24
WO2006077212A1 (en) 2006-07-27
EP1838318A1 (en) 2007-10-03
KR20190135557A (ko) 2019-12-06
KR20210131450A (ko) 2021-11-02
TWI432196B (zh) 2014-04-01
KR20200128451A (ko) 2020-11-12
CN101106996A (zh) 2008-01-16
CA2595043C (en) 2013-11-19
CN101106996B (zh) 2013-10-23
NO20074174L (no) 2007-10-17
NZ555852A (en) 2010-01-29
KR20230170811A (ko) 2023-12-19
AU2006207498A1 (en) 2006-07-27
KR20220165797A (ko) 2022-12-15
ZA200705231B (en) 2008-06-25
AP2249A (en) 2011-07-18
AT9895U1 (de) 2008-05-15
ES2333901T3 (es) 2010-03-02
RS51069B (sr) 2010-10-31
KR20080106991A (ko) 2008-12-09
AP2007004057A0 (en) 2007-08-31
HK1107933A1 (en) 2008-04-25
UA85471C2 (ru) 2009-01-26
PT1838318E (pt) 2009-12-15
ATE446092T1 (de) 2009-11-15
US9271974B2 (en) 2016-03-01
EP1838318B1 (en) 2009-10-21
US20150190393A1 (en) 2015-07-09
DK200700207U1 (da) 2007-08-24
ME01066B (me) 2012-10-20
AU2006207498B2 (en) 2009-11-19
EA013544B1 (ru) 2010-06-30
MY144471A (en) 2011-09-30
IL184530A (en) 2015-01-29
KR20170021905A (ko) 2017-02-28
NO338968B1 (no) 2016-11-07
MX2007007207A (es) 2007-08-15
DE602006009899D1 (de) 2009-12-03
KR20070100368A (ko) 2007-10-10
DK200700207U3 (da) 2007-09-28
AR052880A1 (es) 2007-04-11
DE202006019887U1 (de) 2007-07-26
CA2595043A1 (en) 2006-07-27
SI1838318T1 (sl) 2010-02-26
IL184530A0 (en) 2007-10-31
TW200637554A (en) 2006-11-01
HRP20090679T1 (hr) 2010-01-31
PL1838318T3 (pl) 2010-03-31
KR20140091782A (ko) 2014-07-22
US20080200493A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
EA200701541A1 (ru) Применение оксикодона для лечения висцеральной боли
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
HK1140141A1 (en) Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
NZ603958A (en) Method of treating a musculoskeletal disorder or connective tissue disorder in a subject with prostate cancer with the GNRH antagonist Degarelix
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
MX2007008756A (es) Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
BRPI0904955A2 (pt) Depósito implantável de drogas para reduzir, prevenir ou tratar dor em um paciente em necessidade de tal tratamento e métodos para tratar dor aguda e para fazer um depósito de drogas implantável.
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
CO6680628A2 (es) Uso de ligandos sigma en la hiperalgesia inducida por opioides
DE602004020660D1 (de) Pyrazolylderivative in form von arzneimitteln zur behandlung von akuten oder chronischen neuronalen regressionen
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
BR0214481A (pt) Método e composição para potenciação de um analgésico opiáceo
NL1025873A1 (nl) Doseringsvormen en wijzen van behandeling met vegfr-remmers.
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
WO2006116311A3 (en) Opioid receptor agonist compounds and their use in treatment of pain
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen
WO2011109743A3 (en) Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain
ZA200907646B (en) Axomadol for treating pain from arthritis
IL197769A (en) The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication
WO2007062048A3 (en) Role of proteoglycans in drug dependence

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG RU